Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology. Corvus is developing new drugs and antibodies that block crucial immune checkpoints, and reprogram immune T cells. One of these agents is an oral immune checkpoint inhibitor that has been through human safety testing where it was found to be safe and demonstrated favorable pharmacologic properties. It will enter cancer clinical trials soon. The management team of Corvus includes inventors and scientists who played key roles in the development of Rituxan, Imbruvica and Zelboraf.